Business Trip
En podkast av Greg Kubin & Matias Serebrinsky - Torsdager
59 Episoder
-
The state of psychedelics: Dr. Rachel Yehuda and Zach Haigney (live recording at Soho House)
Publisert: 5.6.2022 -
Empowering the next wave of psychedelic therapists: Journey Clinical
Publisert: 23.5.2022 -
Osmind and the future of electronic health records in psychedelic medicine
Publisert: 18.4.2022 -
Palo Santo on investing in 2nd gen psychedelics and public markets
Publisert: 21.3.2022 -
Designing psychedelic mindstates, with Mindstate Design Labs
Publisert: 10.2.2022 -
PsyMed Ventures, our venture fund to invest in psychedelic medicine & mental health tech
Publisert: 10.1.2022 -
MAPS PBC, rethinking the pharma business model and MDMA-assisted therapy
Publisert: 24.11.2021 -
On transformational ketamine therapy and running an integrative psychedelic clinic
Publisert: 28.10.2021 -
The new frontiers of DMT therapies
Publisert: 6.10.2021 -
Scaling Psilocybin Therapy: Compass Pathways' Lars Wilde
Publisert: 13.8.2021 -
Analyzing the atai Life Sciences IPO
Publisert: 10.6.2021 -
A 30 year journey towards ibogaine approval: Deborah Mash, CEO of DemeRx
Publisert: 4.5.2021 -
Clinical trials, media, reciprocity, open science: Founder of The Trip Report, Zach Haigney
Publisert: 16.3.2021 -
How to (legally) make psychedelic medicine: CEO of Psygen, Danny Motyka
Publisert: 24.2.2021 -
From serving medicine to company founder: NANA founder Flor Bollini
Publisert: 5.1.2021 -
Helping psychedelic practitioners through software: Maya Health CEO David Champion
Publisert: 19.10.2020 -
How to invest in psychedelic companies: Vine Ventures' Founder Ryan Zurrer
Publisert: 17.9.2020 -
Building a psychedelic media company: DoubleBlind's Shelby Hartman and Madison Margolin
Publisert: 13.8.2020 -
Dylan Beynon: ketamine-assisted therapy for anxiety and depression
Publisert: 21.6.2020
Business Trip tells the story of businesses at the frontier of mental health and brain health. Each episode features founders, investors, and researchers in psychedelics, neurotechnology, metabolic psychiatry, digital therapeutics, and more.
